GUD has been the topic of a number of other reports. Scotiabank increased their target price on shares of Knight Therapeutics from C$10.00 to C$10.50 and gave the stock an outperform rating in a report on Friday, December 23rd. TD Securities increased their target price on shares of Knight Therapeutics from C$11.00 to C$12.50 and gave the stock a buy rating in a report on Monday, January 9th. CIBC reduced their target price on shares of Knight Therapeutics from C$13.00 to C$9.80 in a report on Friday, January 13th. Finally, Mackie lowered shares of Knight Therapeutics from a buy rating to a hold rating and reduced their target price for the stock from C$12.00 to C$10.75 in a report on Wednesday, January 4th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of C$11.16.
Shares of Knight Therapeutics (TSE:GUD) opened at 10.10 on Thursday. The stock’s 50 day moving average is $10.56 and its 200-day moving average is $9.93. Knight Therapeutics has a one year low of $7.20 and a one year high of $11.03. The stock has a market capitalization of $1.34 billion and a price-to-earnings ratio of 71.13.
var userip;Your IP Address: document.write(userip);
About Knight Therapeutics
Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.
Receive News & Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.